Publications by authors named "A Koutsokera"
Article Synopsis
- Pneumocystis jirovecii (PJ) is an opportunistic fungus that can cause serious lung infections, particularly in immunocompromised individuals, leading to significant morbidity and mortality.
- While there are established prevention strategies for HIV-infected patients, there is limited research on how to manage PJ infections in non-HIV populations.
- Deciding on prophylaxis for PJ involves evaluating the patient's clinical situation and risk factors, with no strong indicators available to reliably predict Pneumocystis pneumonia (PCP) occurrence; thus, decisions should be personalized.
Article Synopsis
- * The study aimed to isolate bacteria from lung transplant patients' bronchoalveolar lavage fluid that could inhibit the growth of _Aspergillus_ spores using a new enrichment method, resulting in five effective bacterial strains.
- * Although these bacterial strains can inhibit _Aspergillus_ growth, they also caused damage to lung cell cultures, indicating a complex relationship between these bacteria and lung health that requires further investigation.
Allergic bronchopulmonary aspergillosis as an initial manifestation of cystic fibrosis: Diagnostic and therapeutic implications in the era of CFTR modulators.
J Allergy Clin Immunol Glob
November 2024
Allergic bronchopulmonary aspergillosis (ABPA) results from complex hypersensitivity reactions to , which often occur in patients with asthma, cystic fibrosis (CF), or CF transmembrane conductance regulator (CFTR)-related disorders. Genetic predisposition, particularly variants of the gene, probably plays a significant role in the development of ABPA. We present the case of a 20-year-old male with ABPA and bronchiectasis that was initially misdiagnosed as a result of normal sweat chloride values and negative first-level genetic testing results.
View Article and Find Full Text PDFAllergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus spp. ABPA diagnosis may be challenging due to its non-specific presentation. Standard ABPA treatment consists of systemic corticosteroids and antifungal agents.
View Article and Find Full Text PDFBackground: Invasive fungal infections (IFIs) are severe and difficult-to-treat infections affecting immunocompromised patients. Antifungal drug penetration at the site of infection is critical for outcome and may be difficult to achieve. Data about antifungal drug distribution in infected human tissues under real circumstances of IFI are scarce.
View Article and Find Full Text PDF